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AbstrAct
DNA damage activates Checkpoint kinase 1 (Chk1) to halt cell cycle progression 
thereby preventing further DNA replication and mitosis until the damage has been 
repaired. Consequently, Chk1 inhibitors have emerged as promising anticancer 
therapeutics in combination with DNA damaging drugs, but their single agent 
activity also provides a novel approach that may be particularly effective in a subset 
of patients. From analysis of a large panel of cell lines, we demonstrate that 15% 
are very sensitive to the Chk1 inhibitor MK-8776. Upon inhibition of Chk1, sensitive 
cells rapidly accumulate DNA double-strand breaks in S phase in a CDK2- and cyclin 
A-dependent manner. In contrast, resistant cells can continue to grow for at least 
7 days despite continued inhibition of Chk1. Resistance can be circumvented by 
inhibiting Wee1 kinase and thereby directly activating CDK2. Hence, sensitivity to 
Chk1 inhibition is regulated upstream of CDK2 and correlates with accumulation of 
CDC25A. We conclude that cells poorly tolerate CDK2 activity in S phase and that a 
major function of Chk1 is to ensure it remains inactive. Indeed, inhibitors of CDK1 and 
CDK2 arrest cells in G1 or G2, respectively, but do not prevent progression through 
S phase demonstrating that neither kinase is required for S phase progression. 
Inappropriate activation of CDK2 in S phase underlies the sensitivity of a subset of 
cell lines to Chk1 inhibitors, and this may provide a novel therapeutic opportunity for 
appropriately stratified patients.
INtrODUctION
In an undamaged cell, progression through G1, S 
and G2 phase of the cell cycle is dependent on temporal 
activation of cyclin-dependent kinases CDK1 and CDK2 
in complex with cyclins E, A and B. CDK1/2 usually 
exist in a phosphorylated and inactive form that requires 
dephosphoryation for activation at an appropriate time in 
the cell cycle. The inhibitory phosphorylation on tyrosine 
15 and threonine 14 is catalyzed by Wee1 or Myt1 (also 
known as PKMyt1). The subsequent dephosphorylation 
and activation of CDK1/2 is mediated by one of three 
CDC25 phosphatases (A, B or C) [1].
Many anticancer agents damage DNA thereby 
activating a cell cycle checkpoint that arrests cell cycle 
progression and permits repair and recovery. The arrest 
requires activation of Checkpoint kinase 1 (Chk1) that 
inhibits CDC25 and thereby prevents activation of 
CDK1/2 [2]. Consequently, Chk1 inhibitors have been 
developed as potential adjuvants to DNA damaging 
agents as they circumvent arrest before repair is complete, 
drive cells through the cell cycle, and increase cell killing 
[2]. In addition, antimetabolites such as gemcitabine 
and hydroxyurea deprive cells of deoxyribonucleotides 
thereby stalling replication. These stalled replication forks 
are stabilized by Chk1, such that inhibition of Chk1 results 
in replication fork collapse and DNA double-strand breaks 
(DSB) [3, 4]. Wee1 inhibitors have also been shown to 
enhance DNA damage-induced cell killing [5, 6]. Whether 
either of these approaches can elicit cytotoxicity that is 
selective for the tumor cells remains to be established, 
although growth suppression in tumor xenografts suggests 
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these approaches are tolerated [4, 7].
Recently, both Chk1 and Wee1 inhibitors have 
been shown to have single agent activity in some cell 
lines, while the combination of these inhibitors has 
been reported to induce synergistic killing [3, 8-10]. We 
recently reported that U2OS cells are very sensitive to 
short incubation with a low concentration of the Chk1 
inhibitor MK-8776 [11]. The DSB that occur in S phase 
are the result of Mus81-mediated cleavage of DNA, which 
can be prevented by inhibiting the single-strand nuclease 
activity of Mre11, which in turn is dependent on CDK1/2 
[11]. Here, we set out to determine the extent of sensitivity 
in a large panel of cell lines and to define the specific CDK 
that is involved in the induction of DSB in cells sensitive 
to MK-8776. This necessitated a critical reanalysis of the 
methods that discriminate CDK1 from CDK2. 
Tumors frequently exhibit oncogene-induced 
replicative stress, and it has been suggested that this may 
provide a therapeutic opportunity to selectively target 
such cells, in particular through inhibition of Chk1 or its 
upstream activator kinase ataxia telangiectasia-mutated 
and Rad3-related (ATR) [12, 13]. This would suggest a 
large proportion of tumors should be sensitive to Chk1 
inhibition, yet this is not the case. Only a few cell lines are 
sensitive to MK-8776 as a single agent. In contrast, the 
majority of cell lines are sensitive to the Wee1 inhibitor 
AZD1775 (formerly known as MK-1775). It has also been 
suggested that DNA damage induced by either Chk1 or 
Wee1 inhibition results from aberrant mitotic entry [5, 14], 
yet this is also inconsistent with the observations reported 
here. The results suggest that only a subset of cell lines 
activate CDK2 in S phase upon incubation with a Chk1 
inhibitor, and that this might provide a chemical synthetic 
lethal interaction whereby a subset of tumors will respond 
to Chk1 inhibitors as monotherapy.
rEsULts
Differential sensitivity of cells to MK-8776 and 
AZD1775
We recently demonstrated that several cell lines 
are acutely sensitive to the Chk1 inhibitor MK-8776 as a 
single agent [3, 4, 11]. We have expanded this analysis to 
a large panel of cell lines (Figure 1A). In this cytotoxicity 
screen, cells were incubated with drug for either 24 or 48 
h, then the drug was removed and incubation continued 
to 7 days. Alternately, cells were incubated continuously 
for 7 days. Cytotoxicity observed after the shorter 
incubations reflects the inability of the cells to recover 
after a potentially toxic insult. We show that 11 cell lines 
are very sensitive (IC50 < 2 µM) to short incubation with 
MK-8776, while another 9 cell lines are sensitive to this 
concentration after 48 h incubation. However, we now 
show that the majority of cell lines are resistant (IC50 
> 10 µM) and many continue to grow even when MK-
8776 is left in the media for the entire 7 days (Figure 1A). 
These values are comparable to the plasma concentrations 
of MK-8776 in patients where a concentration of > 1 µM 
was maintained for at least 6 h [15].
Resistance to MK8776 does not appear to be due 
to lack of drug bioavailability or defects in Chk1 as these 
cell lines can still be sensitized to either hydroxyurea or 
gemcitabine when incubated with MK-8776 [3, 4]. To 
confirm that Chk1 remained inhibited in the resistant cells 
for a long period, we investigated the impact of MK-8776 
on response of cells to the topoisomerase I inhibitor SN38 
as previously studied [3, 16]. SW620 cells incubated with 
SN38 for 24 h arrested in S phase, but when incubated 
concurrently with SN38 and either 1 or 10 µM MK-
8776, the cells arrested in G2, consistent with abrogation 
of S phase arrest (Figure 1B). Parallel cell cultures were 
plated at low density in the presence of 0, 1 or 10 µM 
MK-8776 and allowed to grow for 6 days at which time 
SN38 was added for the final 24 h. In the absence of MK-
8776, SN38 arrested the cells in S phase as expected. 
However, cells that had been incubated for 6 days in MK-
8776 failed to arrest in S phase when SN38 was added, 
but rather arrested in G2 consistent with concurrent Chk1 
inhibition. A second indication of the activity of Chk1 is 
its autophosphorylation on ser296 that is observed after 
a 24-h incubation with SN38 (Figure 1B). Concurrent 
or 6-day pretreatment with MK-8776 prevented this 
phosphorylation. Similar results were obtained with other 
resistant cell lines (e.g., ADR-Res and MiaPaCa2; data not 
shown). These experiments demonstrate that MK-8776 
continued to inhibit Chk1 for at least 7 days yet these 
resistant cells continued to proliferate.
A subset of cell lines was selected for further 
analysis, and compared for their sensitivity to the Wee1 
inhibitor AZD1775 (Figure 1C). While the majority of 
cell lines appeared to be sensitive to a short incubation 
with AZD1775, a few cell lines appeared to be more 
resistant even to continuous exposure. Importantly, most 
cell lines that were resistant to MK-8776 were sensitive 
to AZD1775. As discussed further below, the cell lines 
resistant to AZD1775 were sensitive to incubation with the 
broad spectrum tyrosine kinase inhibitor PD166285 which 
inhibits both Wee1 and Myt1 [17] (Figure 1C). 
Differential role of cDK1 and cDK2 in regulating 
mitosis and DNA double-strand breaks
The following experiments were designed to 
investigate the mechanisms underlying the differential 
response of cells to MK-8776 and AZD1775. We initially 
studied the pancreas tumor cell line AsPC-1 which is 
acutely sensitive to both drugs, and investigated the 
concentration and time required to induce phosphorylation 
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Figure 1: sensitivity of cell lines to chk1 and Wee1 inhibitors. A. Each cell line was incubated with 0-10 µM MK-8776 for 
either 24 h or 48 h, the drug was removed, and cells incubated in fresh media for an additional 5-6 days. Alternately, cells were incubated 
in drug continuously for 6-7 days. Cells were lysed in the well, stained with Hoechst 33258, and the concentration that inhibited growth 
by 50% was recorded. Each histogram reflects a single 96-well cytotoxicity assay, but sensitivity and resistance of selected cell lines was 
confirmed in subsequent experiments. b. SW620 cells were incubated with 3 ng/ml SN38, alone or concurrently with 1 or 10 µM MK-
8776 for 24 h. Cells were harvested and analyzed by flow cytometry (top). Parallel cultures were seeded at low density, incubated with 0, 
1 or 10 µM MK-8776 for 7 days, and SN38 was added for the final 24 h (middle). Similarly treated cells were also lysed and analyzed for 
Chk1 autophosphorylation by western blotting (bottom). c. A subset of the cell lines was incubated with MK-8776 (data from panel A), 
AZD1775 or PD166285 and analyzed as described in panel A.
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of RPA and H2AX (this phosphorylation on ser139 is 
known as γH2AX) which are commonly used as markers 
of single-stranded DNA and DSB, respectively (Figure 
2A). γH2AX is occasionally reported to occur in the 
absence of DSB although this might be explained by the 
recent observation that stalled replication forks can rapidly 
regress giving a “one-sided DSB” [18]. We previously 
reported that MK-8776 induces γH2AX in U2OS cells that 
is associated with the appearance of DSB in the comet 
assay [11]. Here, we demonstrate the appearance of DSB 
in MK-8776-treated AsPC-1 cells as well (Figure 2B). The 
proportion of cells positive for DSB correlated with the 
proportion of cells positive for γH2AX by flow cytometry 
(Figure 3). We also observed concurrent appearance of 
S4/S8-phosphorylated RPA, a substrate of DNA-protein 
kinase, which in turn is activated by DSB (Figure 2A).
Incubation of AsPC-1 cells with ≥125 nM AZD1775 
for 3 or 6 h caused dephosphorylation of tyrosine 15-
CDK1/2, and the appearance of both γH2AX and 
phospho-RPA (Figure 2A). There was also an increase 
in phospho-histone H3 (pHH3), a common marker for 
mitotic cells. In contrast, MK-8776 induced minimal 
dephosphorylation of CDK1/2 or increase in pHH3, but it 
still induced γH2AX and phospho-RPA at 250 - 500 nM. 
Very similar results were obtained in another sensitive cell 
line, ACHN (Supplemental Figure S1). 
To further contrast the difference between MK-
8776 and AZD1775, we performed 2-dimensional flow 
cytometry to assess the phase of the cell cycle at which 
γH2AX and pHH3 appeared. γH2AX was induced in S 
phase cells by both drugs (Figure 3A; compare rows 1 
and 2). AZD1775 was about 2-fold more potent than MK-
8776, and the majority of S phase cells exhibit γH2AX 
within 6 h (Supplemental Figure S2). A time course 
experiment with MK-8776 demonstrated that, as cells 
continue to enter S, they accumulate in early S phase with 
Figure 2: Impact of MK-8776 and AZD1775 on markers of cDK1/2 activity and DNA double-strand breaks. A. AsPC-1 
cells were incubated with the indicated concentrations of MK-8776 and AZD1775 for 3 or 6 h, then lysed and analyzed by western blotting 
for the indicated proteins. b. AsPC-1 cells were incubated with 2 µM MK-8776 for 6 h and analyzed by the comet assay for the appearance 
of DNA double-strand breaks. Parallel cultures were incubated with MK-8776 plus 5 µM CVT-313. Results are expressed as the percent of 
cells with an d = increase tail moment greater than 85% of the control cells (i.e., 1 SD). The experiment was performed in triplicate (mean 
+/- SE).
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Figure 3: Induction of γH2AX and pHH3 by MK-8776 and AZD1775, and suppression by inhibitors of CDK1 and 
cDK2. A. and b. AsPC-1 cells were incubated with 2 µM MK-8776 or AZD1775 for 6 h alone (row 2) or with the further addition of the 
indicated concentrations of CVT-313, then analyzed by 2-dimensional flow cytometry for DNA content and either γH2AX A. or pHH3 b. 
Cells in the top row received no drug. The inset numbers reflect the percent of cells positive for either γH2AX or pHH3. c. and D. The 
percent of cells positive for γH2AX c. or pHH3 D. in triplicate experiments are reported (mean +/- SE). E. and F. Parallel experiments were 
performed in which Ro3306 was used to suppress γH2AX E. and pHH3 F. induced by MK-8776 and AZD1775.
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high γH2AX (Supplemental Figure S2D). While a small 
proportion of untreated cells exhibited pHH3, these were 
all in G2/M consistent with a few cells passing through 
mitosis. Incubation with AZD1775 but not MK-8776 
induced a significant increase in pHH3 that was only 
observed in the G2/M population (Figure 3B; compare 
rows 1 and 2), and is consistent with activation of the 
mitotic CDK1 (and presumably of aurora kinase B which 
is the ultimate kinase that phosphorylates pHH3; [19]). 
It is important to emphasize that all the γH2AX-positive 
cells are in S phase and so are distinct from the pHH3-
positive cells. Hence, the appearance of γH2AX is not a 
consequence of premature mitosis or mitotic catastrophe. 
These observations highlight a significant difference 
between the two drugs as MK-8776 does not appear to 
activate CDK1. We and others have previously reported 
that inhibition of CDK1/2 can prevent Chk1-inhibitor-
induced γH2AX [11, 20], thereby suggesting that CDK2 
is probably responsible for the induction of γH2AX in S 
phase cells.
Activation of CDK1 or CDK2 is frequently assessed 
as dephosphorylation of tyrosine 15. Unfortunately, 
the phosphotyrosine-15-specific antibodies do not 
discriminate between CDK1 and CDK2 (despite what 
most suppliers state) as the phosphotyrosine resides in the 
middle of a 13 amino acid conserved sequence. We have 
confirmed this by selectively immunoprecipitating CDK2, 
and showing that a purported phosphotyrosine-15-CDK1 
antibody detects the phosphorylated CDK2 (Supplemental 
Figure S3). The failure to detect dephosphorylation 
with MK-8776 (Figure 2; see also Figure 4A) might be 
explained by the continued presence of phospho-CDK1 
masking any dephosphorylation of CDK2. It has been 
reported that CDK1 is present at 10-fold higher levels than 
CDK2 [21], so the phospho-CDK2 would represent a very 
small proportion of the total phospho-CDK1/2. 
To better define the differential involvement of 
CDK1 versus CDK2, we used a small molecule inhibitor, 
CVT-313, which is reported to be about 10-fold more 
selective for CDK2 over CDK1 when tested against 
purified kinases [22]. We found that CVT-313 reduced the 
number of cells exhibiting γH2AX by 50% around 1 µM 
whereas it required about 10 µM to inhibit pHH3 by 50% 
(Figure 3). These results were similar whether γH2AX 
was induced by AZD1775 or MK-8776. Using the comet 
assay, we also demonstrated that CVT-313 prevented the 
appearance of MK-8776-induced DSB (Figure 2B).
To contrast these results, we also used Ro3306 
which is reported to be about 10-fold more selective for 
CDK1 against the purified kinases [23]. However, Ro3306 
inhibited both γH2AX and pHH3 at 2.5 µM suggesting 
that it does not discriminate between CDK1 and CDK2 
in cells (Figure 3E, 3F). This inability of Ro3306 to 
preferentially inhibit CDK1 over CDK2 in cells may 
be attributable to the far lower level of active CDK2 
compared to CDK1 in the cells as discussed above [21]. 
We further compared the efficacy of CVT-313 and 
Ro3306 in otherwise undamaged, but synchronized cells. 
CVT-313 was more effective at preventing progression 
through G1, but Ro3306 was about equipotent at inducing 
G1 and G2 arrest consistent with it inhibiting both CDK1 
and CDK2 (Supplemental Figure S4). Importantly, neither 
inhibitor appeared to prevent progression through S phase.
The results with Ro3306 require additional comment 
as low concentrations caused an increase in pHH3 (Figure 
3; Supplemental Figure S4) and an increase in the 
proportion of cells in G2/M, which we attribute to partial 
inhibition of CDK1 preventing complete passage through 
mitosis. The results with Ro3306 are clearly different 
than those obtained with CVT-313, and are consistent 
with the latter compound preferentially inhibiting CDK2. 
These data further support the model whereby γH2AX 
is a consequence of CDK2 activation, whereas pHH3 is 
a consequence of CDK1 activation. Importantly, MK-
8776 did not activate CDK1 yet both CVT-313 and 
Ro3306 inhibited γH2AX at concentrations that implicate 
inhibition of CDK2.
cyclin E degradation as a marker of cDK2 
activity
Neither HH3 nor H2AX is a direct phosphorylation 
target of CDK1 or CDK2. We therefore sought a more 
direct target. CDK2 complexes with cyclin E and, 
when activated, phosphorylates cyclin E resulting in its 
degradation [24, 25]. This is exactly what was observed 
in several sensitive cell lines (Figure 4A). For example, 
U2OS, ACHN, MDA-MB-435 and TK10 cells show 
degradation of cyclin E upon incubation with MK-
8776 and AZD1775. The degradation of cyclin E was 
prevented by low concentrations of CVT-313 consistent 
with CDK2 inhibition (Figure 4B). Importantly, the 
results show the correlation between inhibition of γH2AX 
and the accumulation of cyclin E further supporting the 
premise that the DNA damage is a consequence of CDK2 
activation. 
Ro3306 also prevented the degradation of cyclin 
E and the appearance of γH2AX at ~2.5 µM which is 
consistent with the data above suggesting that Ro3306 
also inhibits CDK2 at this concentration. Interestingly, 
incubation of these cell lines with either CVT-313 or 
Ro3306 alone also induced accumulation of cyclin E 
(Figure 4C) suggesting that a basal level of CDK2 activity 
provides constitutive turnover of the protein.
Surprisingly, several of the sensitive cell lines 
(AsPC-1, RXF393 and A2780) did not decrease cyclin E 
upon incubation with MK-8776, although it was decreased 
by AZD1775 (Figure 4A). Degradation of cyclin E is 
not solely regulated by CDK2 but by a phosphodegron 
whereby CDK2 phosphorylates ser399 and GSK3B then 
phosphorylates thr395 [25]. Consequently, the degradation 
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Figure 4: Modulation of cyclin E levels by MK-8776, AZD1775 and PD166285. A. The indicated cell lines were incubated 
with 2 µM of each drug for 6 h, then lysed and analyzed by western blotting. The top row reflects cells sensitive to MK-8776. The second 
row reflects cells that are also sensitive to MK-8776, but which fail to degrade cyclin E. The third row reflects MK-8776-resistant cell lines. 
b. The indicated cell lines were incubated concurrently with 2 µM MK-8776 and either 0 - 10 µM CVT-313 (left) or Ro3306 (right) for 6 
h then analyzed by western blotting. c. Cells were incubated with 0 - 10 µM CVT-313 or Ro3306 alone for 6 h, then analyzed by western 
blotting. D. Cells were incubated with 2 µM MK-8776 for 6 h in the presence or absence of 10 µM LY294002 to inhibit PI3-kinase, or 5 
µM CHIR-99021 to inhibit GSK3. Abbreviations: c, control (untreated); 776, MK-8776; 775, AZD1775; 285, PD166285; LY, LY294002; 
CHIR, CHIR-99021. Several images were reordered for clarity of presentation, but in each case the images were derived from the same 
exposure of the same western blot. 
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of cyclin E in U2OS cells was prevented by incubation 
with the GSK3B inhibitor CHIR-99021 (Figure 4D). 
We therefore questioned whether the failure to degrade 
cyclin E in AsPC1 and A2780 cells was due to a lack of 
active GSK3B. The cells were incubated with LY294002 
to inhibit PI3K, which in turn leads to activation of 
GSK3B (confirmed by the decreased phosphorylation of 
ser9), and as a consequence, cyclin E was now degraded 
(Figure 4D). This degradation was also prevented by 
concurrent inhibition of GSK3B by CHIR-99021. These 
results suggest that the failure to degrade cyclin E is not a 
deficiency in activation of CDK2 but rather in the limited 
availability of active GSK3B.
To further dissect the regulation of cyclin E/CDK2 
in the U2OS and AsPC-1 cells, we immunoprecipitated 
cyclin E and assessed the amount of CDK that co-
immunoprecipitated. In both cell lines, a very low level of 
CDK2 was associated with cyclin E either constitutively 
or after incubation with MK-8776; no CDK1 was detected 
(Figure 5A). We also assessed the amount of CDK2 that 
co-immunoprecipated with cyclin A; more CDK2 was 
detected but most still appeared to be unbound (Figure 
5B). These results suggest that the majority of CDK2 
is not associated with either cyclin A or E and therefore 
inactive. These observations are attributed to the fact 
that, unlike CDK1/cyclin B, CDK2 is phosphorylated on 
tyrosine 15 independent of cyclin E or cyclin A, and only 
a small amount then complexes with the cyclins [26]. To 
confirm this hypothesis, we immunoprecipitated CDK2 
to assess its phosphorylation status and indeed found that 
most of the CDK2 remained phosphorylated even when 
cells were incubated with MK-8776 (Supplemental Figure 
S3). In contrast, inhibition of Wee1 prevented the initial 
phosphorylation of CDK2 so no phosphorylation was 
detected. These observations also provide an additional 
explanation as to why little if any dephosphorylation of 
CDK2 was observed upon incubation of cells with MK-
8776; as the majority of phospho-CDK2 is not bound to 
cyclin E or A, it is not subject to dephosphorylation by 
CDC25A.
resistance to MK-8776 is associated with failure 
to activate cDK2
The experiments above suggested that CDK2 
activity is required for sensitivity of cells to both MK-
8776 and AZD1775. We therefore selected several of the 
cell lines that were resistant to MK-8776 (Figure 1). These 
cells failed to dephosphorylate CDK1/2, did not degrade 
cyclin E, and did not accumulate γH2AX (Figure 4A). The 
failure to degrade cyclin E might be attributable to limited 
GSK3B activity as seen for AsPC1 cells. Incubation with 
LY294002 activated GSK3B as judged by decreased 
phosphorylation of ser9-GSK3, but unlike AsPC-1 cells, 
this failed to induce degradation of cyclin E, consistent 
with the failure of MK-8776 to activate CDK2 (Figure 
4D). 
ADR-Res cells were resistant to both MK-8776 and 
Figure 5: Role of cyclin E and cyclin A in inducing γH2AX. A. AsPC-1 (left) and U2OS cells (right) were incubated with 2 µM 
MK-8776 for 6 h, or left untreated, then cyclin E was immunoprecipitated and the amount of associated CDK1 and CDK2 was assessed by 
western blotting. b. AsPC-1 cells were similarly treated but immunoprecipitation was performed with anti-cyclin A antibody. c. AsPC-1 
(left) and ACHN (right) cells were transfected with siRNA targeting either cyclin A, cyclin E, or scrambled control. After 48 h, the cells 
were incubated with 2 µM MK-8776 or AZD1775 for 6 h, and assayed by western blotting for the amount of γH2AX. The asterisk identifies 
a non-specific band in the cyclin E blot for ACHN cells. Abbreviations: 776, MK-8776; 775, AZD1775; IP, immunoprecipitate.
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AZD1775, and this correlated with a failure to activate 
CDK2 as assessed by degradation of cyclin E (Figure 
4A). AZD1775 also failed to induce dephosphorylation of 
CDK1/2 (Figures 4A and 6A). One possible mechanism 
of resistance to AZD1775 is that they rely on Myt1 to 
prevent activation of CDK1/2. We are unaware of any 
selective inhibitors of Myt1, but PD166285 is a broad 
tyrosine kinase inhibitor that inhibits both Wee1 and Myt1 
[17]. All the cell lines were sensitive to a 24-h incubation 
with PD166285 (Figure 1C), and γH2AX was observed 
preferentially in S phase cells with potency similar to 
both MK-8776 and AZD1775 (Supplemental Figure 
S2C). ADR-Res cells incubated with PD166285 exhibited 
dephosphorylation of CDK1/2, and phosphorylation of 
RPA, H2AX and HH3 within 6 h (Figure 6). This acute 
sensitivity of ADR-Res cells suggests that resistance to 
AZD1775 might be mediated by Myt1. 
cyclin A/cDK2 is responsible for the appearance 
of γH2AX
CDK2 normally partners with both cyclin E and 
cyclin A. The results above have correlated the activation 
of cyclin E/CDK2 with sensitivity to MK-8776 and 
AZD1775. However, the DSB could equally be the 
consequence of activation of cyclin A/CDK2, and CDK2 
did immunoprecipitate with both cyclins (Figure 5A and 
5B). To address this possibility, we transfected cells with 
siRNA targeting either cyclin E or cyclin A. In both AsPC-
1 and ACHN cells, the suppression of cyclin A, but not 
cyclin E, resulted in suppression of γH2AX (Figure 5C). 
As CDK1 did not immunoprecipitate with cyclin A (Figure 
5B), these results support the contention that cyclin A/
CDK2 activation is critical for the onset of DSB. 
MK-8776-mediated accumulation of cDc25A 
predicts sensitivity to MK-8776
The activation of CDK2 is a consequence of its 
dephosphorylation by CDC25A which, in turn, is a 
direct target of Chk1. Phosphorylation by Chk1 causes 
degradation of CDC25A and maintains low basal levels of 
CDC25A [27]. Therefore, we assessed the impact of MK-
8776 on the levels of CDC25A. In six sensitive cell lines, 
MK-8776 induced accumulation of CDC25A, consistent 
with the observed activation of CDK2 (Figure 7A). In 
contrast, five resistant cell lines exhibited no change in 
CDC25A levels consistent with the failure of MK-8776 
to activate CDK2. There was a large range of levels of 
CDC25A across the cell lines requiring multiple exposures 
of the western blots to show the differences; one cell line, 
ADR-Res, expressed no detectable protein (note the AsPC-
1 lysate is shown in both blots for direct comparison of 
levels). Interestingly, there is no correlation between basal 
CDC25A levels and sensitivity to MK-8776.
Figure 6: Mechanism of resistance of ADr-res cells to MK-8776. ADR-Res cells were incubated with the indicated concentrations 
of either MK-8776, AZD1775 or PD166285 for 6 h, then analyzed by western blotting. These cells were only sensitive to PD166285 and 
only showed increased γH2AX and pHH3 at concentrations that inhibited pY15-CDK1/2. 
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DIscUssION
By screening a large number of cell lines, we have 
established that only about 15% are hypersensitive to the 
Chk1 inhibitor MK-8776 following a 24-h incubation 
(IC50 < 2 µM). Our cytotoxicity assay differs from more 
commonly used continuous incubations of cells with 
drug as it assesses the ability of cells to recover over 6 
days following a short incubation. In this regard, it more 
closely approximates a clonogenic assay. Furthermore, 
the short incubation with drug might better reflect what 
can be achieved upon administration to a patient. It also 
demonstrates a potential therapeutic window that is based 
on both dose and time of administration. For example, 
a non-transformed, but immortalized breast cell line 
(IMEC) was completely resistant to a 48-h incubation 
and only showed a slight growth inhibition after 7 days. 
MK-8776 continued to inhibit Chk1 in resistant cells for 
7 days without impeding their growth. This differs from 
experiments in mice in which deletion of Chk1 led to 
Figure 7: Impact of MK-8776 on cDc25A levels in sensitive and resistant cells. A. Sensitive (top) and resistant cells (bottom) 
were incubated with MK-8776 for 6 h, then analyzed by western blotting for changes in level of CDC25A protein. AsPC-1 cells are 
included in both panels for comparison. Several exposures are shown of each blot. Each lane contained lysate from 20,000 cells. PARP was 
used as a loading control; while it differs in level between cell lines, it demonstrates equal loading between control and treated samples for 
each line. b. Model of the signaling pathway impacted by Chk1 in MK-8776-sensitive and resistant cells. A role for any of the alternate 
kinases (GSK3, PLK3, CK1/ε and NEK11) in eliciting resistance remains to be established. The box demonstrates how the Wee1 inhibitor 
AZD1775 activates CDK2 in both MK-8776-sensitive and resistant cells.
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embryonic lethality [28, 29]. Previous experiments have 
been performed with U2OS cells that are sensitive to Chk1 
inhibition [30], but those studies failed to recognize that 
the majority of cell lines can tolerate inhibition of Chk1 
for long periods.
Sensitivity to Chk1 inhibition was observed as 
rapid induction ( < 6 h) of γH2AX in S phase cells. As 
more cells progress from G1 into S, they also succumb 
to Chk1 inhibition and exhibit high γH2AX. Prior 
experiments have demonstrated that the γH2AX in U2OS 
cells correlates with the appearance of DSB [11], and 
this was confirmed for AsPC-1 cells in this study. These 
DSB were prevented by CVT-313 at concentrations 
that selectively inhibit CDK2, and by siRNA-mediated 
suppression of cyclin A. CDK2 is required for replication 
origin firing and is therefore suppressed by Chk1 [31]. 
Chk1 inhibition in early S phase leads to premature firing 
of late replication origins, which may result in collision 
of these late replicons with ongoing transcription, R loop 
formation and replication fork collapse [32]. Whether this 
pathway is involved in the observed cytotoxicity remains 
to be determined, but downstream effectors, Mre11 and 
Mus81 nucleases, have been implicated in the eventual 
DNA breakage [11, 33, 34]. 
It was unexpected to find that cells do not tolerate 
increased CDK2 activity in S phase, although, in 
retrospect, this has been reported previously using a CDK2 
variant that can not be phosphorylated on thr14 and tyr15 
[35]. In contrast, CDK2 is usually considered essential for 
progression through S phase, as it is required for loading 
Cdc45 on to DNA to initiate the firing of each replication 
fork [31]. However, we observed that incubation of 
undamaged cells with CVT-313 failed to arrest cells in 
S phase suggesting that this requirement for CDK2 can 
be circumvented. Incubation of undamaged cells with 
CVT-313 did cause accumulation of cyclin E suggesting 
that there is sufficient constitutive CDK2 activity to limit 
cyclin E/CDK2. It is possible that there is a threshold level 
of activity of CDK2 below which cells survive, but which, 
once exceeded, leads to DSB. Cells may activate CDK2 
in S phase as a stress response that permits circumvention 
of blocked replication by activating alternate replicons. 
Hence, there must be a careful balance between the CDK2 
activity required for replication recovery versus induction 
of extensive DNA fragmentation. 
The majority of cell lines were resistant to Chk1 
inhibition. Resistance did not correlate with any particular 
organ site or p53 status. While the observed DSB might 
induce a p53 response, that would occur after activation 
of CDK2 so could not prevent the damage. Several cell 
lines had been selected for other phenotypes that might 
contribute to sensitivity (e.g., 2008, a FANCF-defective 
ovarian line; ATLD1, isolated from a patient defective for 
Mre11), but they, and their complemented derivatives, 
remained resistant to MK-8776 in our analysis (Figure 1).
To begin to understand the mechanism of resistance 
to MK-8776, we asked whether more direct activation 
of CDK2 using the Wee1 inhibitor AZD1775 would 
circumvent resistance. Inhibition of Wee1 was cytotoxic 
to most of the cell lines, and the few resistant lines were 
sensitive to dual inhibition of Wee1 and Myt1. MK-
8776-resistant cells failed to activate CDK2 or degrade 
cyclin E (a consequence of CDK2 activation) in response 
to Chk1 inhibition. This compared to the sensitive 
cells that activated CDK2 and, in most cases, degraded 
cyclin E. Several sensitive cells failed to degrade cyclin 
E, but this was attributed to limited activity of GSK3B, 
whose activity is also required to phosphorylate the 
phosphodegron in cyclin E that leads to its degradation. In 
contrast, activation of GSK3B in resistant cells, in concert 
with MK-8776, did not lead to degradation of cyclin E. 
These results suggest that the mechanism of resistance 
to MK-8776 is mediated upstream of CDK2 activation 
(Figure 7B). In support of this conclusion, MK-8776 
induced accumulation of CDC25A only in the sensitive 
cells. CDC25A regulation is complex with input from 
multiple other kinases resulting in either degradation 
or sequestration depending on cell cycle phase [36-39]. 
Future studies will be directed to defining the critical 
proteins that regulate CDC25A and discriminate sensitive 
and resistant cells.
It has previously been demonstrated that the Wee1 
inhibitor can force S phase-arrested cells to directly enter 
mitosis without completing DNA synthesis, albeit only in 
some cell lines [5, 14]. It was suggested this was a novel 
mechanism of action whereby unscheduled entry into 
mitosis explained the underlying sensitivity to AZD1775. 
However, we demonstrate that extensive γH2AX can 
occur in S phase upon incubation with either MK-8776 or 
AZD1775, and these cells are distinct from those positive 
for pHH3, demonstrating that mitotic events are not 
required for the DSB observed here. 
These experiments required a critical reevaluation 
of the tools available to discriminate CDK1 from CDK2. 
Many suppliers provide antibodies that are purported to 
detect phosphotyrosine on CDK1, while other antibodies 
are purported to detect the phosphotyrosine on CDK2. 
However, this is a highly conserved epitope in both 
proteins and the antibodies do not discriminate the two 
kinases. The use of siRNA to suppress one or other 
kinase can also be misleading as this can arrest cell cycle 
progression in G1 or G2 and thereby protect cells from 
a drug that requires S phase progression. We found that 
the commonly used CDK1-selective inhibitor Ro3306 was 
equally effective at inhibiting CDK2. This observation 
may relate to the much lower level of CDK2 present 
in cells compared to CDK1, and also to the very small 
proportion of CDK2 that complexes with either cyclin E 
or cyclin A [21, 26]. We conclude that CVT-313 is more 
selective for CDK2 and this was a major tool to help 
understand the critical role of CDK2. Many substrates 
can be phosphorylated by both CDK1 and CDK2, but 
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cyclin E should be a selective target for CDK2 as they 
form a heterodimeric complex. The fact that cyclin E was 
degraded whenever CDK2 was active was also a useful 
tool in these studies, but with the proviso that concurrent 
GSK3B-mediated phosphorylation is also required for 
cyclin E degradation. An interesting extrapolation of these 
observations is that cells or tumors with elevated cyclin E 
protein probably reflect cells with inactive CDK2. 
Several Chk1 inhibitors have been combined with 
DNA damaging agents in clinical trials, though several 
were terminated because of toxicity [2, 40]. Many of 
the drugs are not pure Chk1 inhibitors, so it is not clear 
whether the toxicity is due to off-target effects. For 
example, a recent report showed that three Chk1 inhibitors 
also inhibit FLT3 [41]. MK-8776 is possibly one of the 
most selective inhibitors, and clinical trials have been 
performed in combination with both cytarabine and 
gemcitabine; partial responses were observed but further 
development has been terminated for business reasons 
[15, 42, 43]. A Phase I clinical trial of GDC0425 plus 
gemcitabine continues (www.clinicaltrials.gov) though the 
selectivity of this compound has not yet been reported. The 
only clinical trial testing a Chk1 inhibitor as monotherapy 
involves LY2606368, although this compound also 
inhibits a variety of other kinases including Chk2 and 
RSK1-3. Unfortunately no attempt has been made to 
stratify patients who might respond. This is critical if 
Chk1 inhibitors are to succeed as monotherapy.
In summary, we conclude that CDK2 is usually 
repressed in S phase cells, and its untimely activation 
explains the sensitivity to Chk1 and Wee1 inhibitors as 
single agents. The mechanism of resistance to MK-8776 
appears to rely on redundant pathways that regulate 
CDC25A, whereas the sensitive cells appear to rely 
solely on Chk1. Identification of the critical determinants 
of response is required so that appropriate patients 




The majority of cell lines were derived from the 
NCI-60 panel and obtained from the Developmental 
Therapeutics Program, National Cancer Institute. Other 
cell lines were obtained from the American Type Culture 
Collection, or described in our previous papers [3, 11]. 
Cells were maintained in RPMI1640 plus 10% fetal 
bovine serum, antibiotic and antimycotic.
chemicals
MK-8776 and AZD1775 were provided by Merck. 
PD166285, CVT-313, Ro3306, LY294002 and CHIR-
99021 were obtained from Sigma. SN38 was provided 
by Pfizer. Stock solutions were made at 10 mM in 
dimethylsulfoxide (CHIR-99021 at 5 mM; SN38 100 µM). 
SMART pool siRNA for cyclin E (CCNE1) and cyclin A2 
(CCNA2) were obtained from Dharmacon.
Growth inhibition assays
Inhibition of cell growth was assessed by plating 
500 - 5000 cells (depending on growth rate) per well of 
a 96-well plate. The following day, drugs were added 
as 2-fold dilutions from 10 µM (8 wells/concentration). 
After 24 and 48 h, drug was removed, and replaced with 
fresh media. A third plate was continuously incubated 
with drug. Before reaching confluence (6 - 7 days), cells 
were washed, lysed and stained with Hoechst 33258 as 
previously described [3, 44]. Fluorescence was read on a 
microplate spectrofluorometer. 
Antibodies and immunoblotting
For protein analysis, cells were incubated with 
drugs in 6-well plates, rinsed, lysed in Laemmli sample 
buffer and boiled for 5 min. Proteins were separated by 
SDS-PAGE and transferred to polyvinylidene difluoride 
membranes. Western blotting was performed with the 
following antibodies: p-Y15-CDK1 (also detects phospho-
CDK2 (cst-9111)), p296-Chk1 (cst-2349), γH2AX (cst-
9718), cyclin A2 (cst-4656), pS9-GSK3B (cst-9331), 
pHH3 (cst-3377) (Cell Signaling Technology); Chk1 (sc-
8404), cyclin E (sc-247) (Santa Cruz Biotechnology Inc.); 
CDK1 (8878), CDK2 (05-596) (Millipore); CDC25A (ms-
638; Thermo Scientific); RPA (ab-2175; Abcam); pS4/S8-
RPA (NBP 1-23017; Novus); actin (A3854; Sigma). 
Immunoprecipitation
Cells were lysed in lysis/wash buffer provided in 
the Classic Magnetic IP/Co-IP Kit (Pierce, 8804) with 
added protease and phosphatase inhibitors for 30 min on 
ice, then centrifuged at 13,000g for 10 min. The extract 
(500 μg) was pre-cleared with Protein A/G magnetic 
beads for 1 h at 4 °C and the supernatant was collected. 
Antibody [2.5 µg; cyclin E (sc-198), cyclin A (sc-751)] 
was added to the supernatant and mixed for 3 h at 4 °C. 
Pre-washed magnetic beads were added and incubated on 
a rotator at 4°C overnight. The supernatant was recovered, 
and the immunoprecipitate was washed and resuspended 
in 2 x Laemmli sample buffer. Equivalent portions of 
supernatant and immunoprecipitate were subjected to 
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10% polyacrylamide SDS-PAGE and immunoblotting 
performed for the proteins indicated.
cell cycle analysis
Cell cycle analysis was conducted by flow cytometry 
using propidium iodide as described previously [4]. For 
2-dimensional flow cytometry, cells were also labeled with 
Alexa 488-conjugated γH2AX or pHH3 (Cell Signaling 
Technology). Cells were analyzed on either a Becton 
Dickinson FACScan or FACScalibur flow cytometer.
comet assay
AsPC-1 cells were incubated with MK-8776 alone, 
or in combination with CVT-313 for 6 hours. 
Preparation and execution of the neutral comet assay 
was done according to the Trevigen Comet Assay protocol 
for single-cell gel electrophoresis. The slides were imaged 
with a fluorescent microscope, and comet tails were scored 
using ImageJ software. The tail moment for the control 
was calculated and a threshold value set at 1 standard 
deviation above the mean. Results are expressed as the 
percent of cells with a tail moment above 1SD of the 
control.
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